Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;8(1):101–120. doi: 10.1111/j.1750-3639.1998.tb00139.x

Peroxisomal Disorders: Genotype, Phenotype, Major Neuropathologic Lesions, and Pathogenesis

James M Powers 1,✉, Hugo W Moser 2
PMCID: PMC8098283  PMID: 9458170

Abstract

Neurological dysfunction is a prominent feature of most peroxisomal disorders. Enormous progress in defining their gene defects has been achieved. The genes and gene products, peroxins (PEX), in five of the complementation groups have been defined. These studies confirm that Zellweger syndrome (ZS), neonatal adrenoleukodystrophy (NALD), and infantile Refsum disease (IRD) are a disease continuum. The gene defect in adreno‐leukodystrophy (ALD) / adrenomyeloneuropathy (AMN) involves an integral peroxisomal membrane protein. Neuropathologic lesions are of three major classes: (i) abnormalities in neuronal migration or differentiation, (ii) defects in the formation or maintenance of central white matter, and (iii) postdevelopmental neuronal degenerations. The central white matter lesions are those of: (i) inflammatory demyelination, (ii) non‐inflammatory dysmyelination, and (iii) nonspecific reductions in myelin volume or staining with or without reactive astrocytosis. The neuronal degenerations are of two major types: (i) the axonopathy of AMN involving ascending and descending tracts of the spinal cord, and (ii) cerebellar atrophy in rhizomelic chondrodysplasia punctata and probably IRD. We postulate that the abnormal fatty acids in peroxisomal disorders, particularly very long chain fatty acids and phytanic acid, are incorporated into cell membranes and perturb their microenvironments resulting in dysfunction, atrophy and death of vulnerable cells. The advent of mouse models for ZS and ALD is anticipated to provide even greater pathogenetic insights into the peroxisomal disorders.

Full Text

The Full Text of this article is available as a PDF (356.2 KB).

References

  • 1. Agamanolis DP, Novak RW (1995) Rhizomelic chondrodysplasia punctata: report of a case with review of the literature and correlation with other peroxisomal disorders. Ped Pathol Lab Med 15: 503–513. [DOI] [PubMed] [Google Scholar]
  • 2. Aubourg P (1996) X‐linked adrenoleukodystrophy. In: Handbook of Clinical Neurology, Vinken PJ, Bruyn GW (eds.), Neurodystrophies and Neurolipidoses, Moser HW (ed.), Chapter 21, pp. 447–484, Elsevier Science Publishers: Amsterdam . [Google Scholar]
  • 3. Baes M, Gressens P, Baumgart E, Carmeliet P, Casteels M, Fransen M, Evrard P, Fahimi D, Declercq PI, Collen D, Van Veldhoven PP, Mannaerts GP (1977) A mouse model for Zellweger syndrome. Nature Genet 17: 49–57. [DOI] [PubMed] [Google Scholar]
  • 4. Berger J, Molzer B, Fae I, Bernheimer H (1994) X‐linked adrenoleukodystrophy (ALD): a novel mutation of the ALD gene in 6 members of a family presenting with 5 different phenotypes. Biochem Biophys Res Commun 205: 1638–1643. [DOI] [PubMed] [Google Scholar]
  • 5. Bizzozero OA, Zuniga G, Lees MB (1991) Fatty acid composition of human proteolipid protein in peroxisomal disorders. J Neurochem 56: 872–878. [DOI] [PubMed] [Google Scholar]
  • 6. Boles DJ, Craft DA, Padgett DA, Loria RM, Rizzo WB (1991) Clinical variation in X‐linked adrenoleukodystrophy: fatty acid and lipid metabolism in cultured fibroblasts. Biochem Med Metab Biol 45: 74–91. [DOI] [PubMed] [Google Scholar]
  • 7. Braverman N, Dodt G, Gould SJ, Valle D (1995) Disorders of peroxisome biogenesis. Hum Mol Genet 4: 1791–1798. [DOI] [PubMed] [Google Scholar]
  • 8. Braverman N, Steel G, Obie C, Moser A, Moser H, Gould SJ, Valle D (1997) Human PEX 7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata. Nature Genet 15: 369–376. [DOI] [PubMed] [Google Scholar]
  • 9. Budka H, Sluga E, Heiss W‐D (1976) Spastic paraplegia associated with Addison's disease: Adult variant of adrenoleukodystrophy. J Neurol Sci 213: 237–250. [DOI] [PubMed] [Google Scholar]
  • 10. Cartier N, Lopez J, Mouiller P, Rocchiccioli F, Rolland MO, Jorge P, Mosser J, Mandel JM, Bougneres PF, Danos O, Aubourg P (1995) Retroviral‐mediated gene transfer corrects very‐long‐chain fatty acid metabolism in adrenoleukodystrophy fibroblasts. Proc Natl Acad Sci USA 92: 1674–1678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Chang C‐C, Lee W‐H, Moser HW, Valle D, Gould SJ (1997) Isolation of the human PEX 12 gene, mutated in group 3 of the peroxisome biogenesis disorders. Nature Genet 15: 385–388. [DOI] [PubMed] [Google Scholar]
  • 12. Chow CW, Poulos A, Fellenberg AJ, Christodoulou J, Danks DM (1992) Autopsy findings in two siblings with infantile Refsum disease. Acta Neuropathol (Berl) 83: 190–195. [DOI] [PubMed] [Google Scholar]
  • 13. Clayton PT, Eckhardt S, Wilson J (1994) Isolated dihydroxyacetonephosphate acyltransferase deficiency presenting with developmental delay. J Inher Metab Dis 17: 315–318. [DOI] [PubMed] [Google Scholar]
  • 14. Cohen SMZ, Brown FR, Martyn L, Moser HW, Chen W, Kristenmacher M, Punnett H, Graver W, De La Cruz ZC, Chan NR, Green WR (1983) Ocular histopathologic and biochemical studies of the cerebrohepatorenal syndrome (Zellweger's syndrome) and its relationship to neonatal adrenoleukodystrophy. Am J Ophthal 96: 488–501. [DOI] [PubMed] [Google Scholar]
  • 15. Danpure CJ, Purdue PE (1995) Primary hyperoxaluria at the cellular level. In: The Metabolic and Molecular Basis of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, Valle D (eds.), 7th Edition, Chapter 75, pp. 2385–2424, McGraw‐Hill: New York . [Google Scholar]
  • 16. Dimmick JE, Applegarth DA (1993) Pathology of peroxisomal disorders. In: Genetic Metabolic Diseases, Landing BH, Haust MD, Bernstein J, Rosenberg HS (eds.), Per-spect Pediatr Pathol 17: 45–98. [PubMed] [Google Scholar]
  • 17. Distel B, Erdmann R, Gould SJ, Blobel G, Crane DI, Cregg JM, Dodt G, Fujiki Y, Goodman JM, Just WW, Kiel JAKW, Kunau W‐H, Lazarow PB, Mannaerts GP, Moser HW, Osumi T, Rachubinski RA, Roschev A, Subramani S, Tabak HFT, Sukamoto T, Valle D, van der Klei I, Van Veldhoven PP, Veenhuis M (1996) A unified nomenclature for peroxisome biogenesis factors. J Cell Biol 135: 1–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Dodt G, Braverman N, Wong C, Moser A, Moser HW, Watkins P, Valle D, Gould SJ (1995) Mutations in the PTS1 receptor gene, PXR 1, define complementation group 2 of the peroxisome biogenesis disorders. Nature Genet 9: 115–124. [DOI] [PubMed] [Google Scholar]
  • 19. Eaton JW, Ma M (1995) Acatalasemia. In: The Metabolic and Molecular Basis of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, Valle D (eds.), 7th Edition, Chapter 74, pp. 2371–2383, McGraw‐Hill: New York . [Google Scholar]
  • 20. Edwin D, Speedie LJ, Kohler W, Naidu S, Kruse B, Moser HW (1996) Cognitive and brain magnetic resonance imaging findings in adrenomyeloneuropathy. Ann Neurol 40: 675–678. [DOI] [PubMed] [Google Scholar]
  • 21. Esiri MM, Hyman NM, Horton WL, Lindenbaum RH (1984) Adrenoleukodystrophy: clinical, pathological, and biochemical findings in two brothers with the onset of cerebral disease in adult life. Neuropathol Appl Neurobiol 10: 429–435. [DOI] [PubMed] [Google Scholar]
  • 22. Evrard P, Caviness VS, Prats‐Vinas J, Lyon G (1978) The mechanism of arrest of neuronal migration in the Zellweger malformation: an hypothesis based upon cytoar‐chitectonic analysis. Acta Neuropathol (Berl) 41: 109–117. [DOI] [PubMed] [Google Scholar]
  • 23. Faust PL, Hatten ME (1997) Targeted deletion of the PEX 2 peroxisome assembly gene in mice provides a model for Zellweger syndrome, a human neuronal migration disorder. J Cell Biol, in press. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Fournier B, Saudubray LJM, Benichov B, Lyonnet S, Munnich A, Clevers H, Poll‐The BT (1994) Large deletion of the peroxisomal acyl‐CoA oxidase gene in pseudoneonatal adrenoleukodystrophy. J Clin Invest 94: 526–531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Fournier B, Smeitink AM, Dorland L, Berger R, Saudubray LJM, Poll‐The BT (1994) Peroxisomal disorders: a review. J Inher Metab Dis 17: 470–486. [DOI] [PubMed] [Google Scholar]
  • 26. Fukuda S, Shimozawa N, Suzuki Y, Zhang Z, Tomatsu S, Tsukamoto T, Hashiguchi N, Osumi T, Masuno M, Imizumi K (1996) Human peroxisomal assembly factor‐2 (PAF‐2): a gene responsible for group C peroxisome biogenesis disorder in humans. Am J Hum Genet 59: 1210–1220. [PMC free article] [PubMed] [Google Scholar]
  • 27. Ghatak NR, Nochlin D, Peris M, Myer EC (1981) Morphology and distribution of cytoplasmic inclusions in adrenoleukodystrophy. J Neurol Sci 50: 391–398. [DOI] [PubMed] [Google Scholar]
  • 28. Goldfischer S, Collins J, Rapin I, Neumann P, Neglia W, Spiro AJ, Ishii I, Roels F, Vamecq J, Van Hoof F (1986) Pseudo‐Zellweger syndrome: Deficiencies in several peroxisomal oxidative activities. J Pediatr 108: 25–32. [DOI] [PubMed] [Google Scholar]
  • 29. Hamilton JA, Era S, Bhamidipati SP, Reed RG (1991) Locations of the three primary binding sites for long‐chain fatty acids on bovine serum albumin. Proc Natl Acad Sci USA 88: 2051–2054. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Hauser SL (1995) Tumor necrosis factor: immunogenetics and disease, (editorial comment). Ann Neurol 38: 702–704. [DOI] [PubMed] [Google Scholar]
  • 31. Heymans HSA, Wanders RJA (1996) Rhizomelic chondrodysplasia punctata. In: Handbook of Clinical Neurology, Vinken PJ, Bruyn GW (eds.), Neurodystrophies and Neurolipidoses, Moser HW (ed.), Volume 66, Chapter 24, pp. 525–534, Elsevier Science Publishers: Amsterdam . [Google Scholar]
  • 32. Higgins CF (1992) ABC transporters: from microorganisms to man (Review) Ann Rev Cell Biol 8: 67–113. [DOI] [PubMed] [Google Scholar]
  • 33. Ho JK, Moser H, Kishimoto Y, Hamilton JA (1995) Interactions of a very long chain fatty acid with model membranes and serum albumin: implications for the pathogenesis of adrenoleukodystrophy. J Clin Invest 96: 1455–1463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Igarashi M, Schaumburg HH, Powers J, Kishimoto Y, Kolodny E, Suzuki K (1976) Fatty acid abnormality in adrenoleukodystrophy. J Neurochem 26: 851–860. [DOI] [PubMed] [Google Scholar]
  • 35. Igarashi M, Belchis D, Suzuki K (1976) Brain gangliosides in adrenoleukodystrophy. J Neurochem 27: 327–328. [DOI] [PubMed] [Google Scholar]
  • 36. Igarashi M, Neely JG, Anthony PF, Alford BR (1976) Cochlear nerve degeneration coincident with adrenocerebroleukodystrophy. Arch Otolaryngol 102: 722–726. [DOI] [PubMed] [Google Scholar]
  • 37. Jaffe R, Crumrine P, Hashida Y, Moser HW (1982) Neonatal adrenoleukodystrophy. Clinical, pathologic, and biochemical delineation of a syndrome affecting both males and females. Am J Pathol 108: 100–111. [PMC free article] [PubMed] [Google Scholar]
  • 38. Johnson AB, Schaumburg HH, Powers JM (1976) Histochemical characteristics of the striated inclusions of adrenoleukodystrophy. J Histochem Cytochem 24: 725–730. [DOI] [PubMed] [Google Scholar]
  • 39. Kamijo K, Taketani S, Yokota S, Osumi T, Hashimoto T (1990) The 70‐KDa peroxisomal membrane protein is a member of Mdr (P glycoprotein)‐related ATP‐binding protein superfamily. J Biol Chem 265: 4534–4540. [PubMed] [Google Scholar]
  • 40. Kaufmann WE, Theda C, Naidu S, Watkins PA, Moser AB, Moser HW (1996) Neuronal migration abnormality in peroxisomal bifunctional enzyme defect. Ann Neurol 39: 268–271. [DOI] [PubMed] [Google Scholar]
  • 41. Kelley RI, Datta NS, Dobyns WB, Hajra AK, Moser AB, Noetzel MJ, Zackai EH, Moser HW (1986) Neonatal adrenoleukodystrophy: New cases, biochemical studies and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. Am J Med Genet 23: 869–901. [DOI] [PubMed] [Google Scholar]
  • 42. Kemp S, Ligtenberg MJ, Van Geel BM, Barth BG, Wolter‐man RA, Schoute F, Sarde CO, Mandel JL, Van Oost BA, Bolhuis PA (1994) Identification of a two base pair deletion in five unrelated families with adrenoleukodystrophy: a possible hot spot for mutations. Biochem Biophys Res Commun 202: 647–653. [DOI] [PubMed] [Google Scholar]
  • 43. Knazek RA, Rizzo WB, Schulman JD, Dave JR (1983) Membrane microviscosity is increased in the erythrocytes of patients with adrenoleukodystrophy and adrenomyeloneuropathy. J Clin Invest 72: 245–248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Kobayashi T, Shinnoh N, Kondo A, Yamada T (1995) Adrenoleukodystrophy protein deficient mice represent abnormality of very long chain fatty acid metabolism. Biochem Biophys Res Commun 232: 631–636. [DOI] [PubMed] [Google Scholar]
  • 45. Kok F, Neumann S, Sarde CO, Zheng S, Wu KH, Wei HM, Bergin J, Watkins PA, Gould S, Sack G, Moser H, Mandel JL, Smith KD (1995) Mutational analysis of patients with X‐linked adrenoleukodystrophy. Hum Mutat 6: 104–115. [DOI] [PubMed] [Google Scholar]
  • 46. Korenke GC, Hunneman DH, Kohler W, Stockier S, Landmark K, Hanefeld F (1995) Glyceroltrioleate/glyceroltrierucate therapy in 16 patients with X‐chromosomal adrenoleukodystrophy/adrenomyeloneuropathy: Effect on clinical, biochemical and neurophysiological parameters. Eur J Pediatr 154: 64–70. [DOI] [PubMed] [Google Scholar]
  • 47. Korenke GC, Fuchs S, Krasemann E, Doerr HG, Wilichowski E, Hunneman DH, Hanefeld F (1996) Cerebral adrenoleukodystrophy (ALD) in only one of monozygotic twins with an identical ALD genotype. Ann Neurol 40: 254–257. [DOI] [PubMed] [Google Scholar]
  • 48. Krivit W, Lockman LA, Watkins PA, Hirsch J, Shapiro EG (1995) The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J Inher Metab Dis 18: 398–412. [DOI] [PubMed] [Google Scholar]
  • 49. Kruse B, Barker PD, Van Zijl PCM, Duyn JH, Moonen CTW, Moser HW (1994) Multislice proton MR spectro‐scopic imaging in X‐linked adrenoleukodystrophy. Ann Neurol 36: 595–608. [DOI] [PubMed] [Google Scholar]
  • 50. Kumar AJ, Rosenbaum AE, Naidu S, Wener L, Citrin CM, Lindenberg R, Kim WS, Ziureich SJ, Molliver ME, Mayber HS, Moser HW (1987) Adrenoleukodystrophy: Correlating MR imaging with CT. Radiology 165: 497–504. [DOI] [PubMed] [Google Scholar]
  • 51. Kumar AJ, Kohler W, Kruse B, Naidu S, Bergin A, Edwin D, Moser HW (1995) MR findings in adult‐onset adrenoleukodystrophy. Am J Neuroradiol 16: 1227–1237. [PMC free article] [PubMed] [Google Scholar]
  • 52. Kuroda S, Hirano A, Yuasa S (1983) Adrenoleukodystrophy: Cerebello‐brainstem dominant case. Acta Neuropathol (Berl) 60: 149–152. [DOI] [PubMed] [Google Scholar]
  • 53. Lazarow PB, Moser HW (1995) Disorders of peroxisomal biogenesis. In: The Metabolicand Molecular Basis of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, Valle (eds.), Chapter 71, pp. 2287–2324, McGraw‐Hill: New York . [Google Scholar]
  • 54. Lazarow PB (1995) Peroxisomal structure, function and biogenesis ‐ Human patients and yeast mutants show strikingly similar defects in peroxisome biogenesis. J Neuropathol Exp Neurol 54: 720–725. [DOI] [PubMed] [Google Scholar]
  • 55. Leaf A (1995) Omega‐3 fatty acids and prevention of ventricular fibrillation. Prostaglandins, Leukotrienes and Essential Fatty Acids 52: 197–198. [DOI] [PubMed] [Google Scholar]
  • 56. Lombard‐Platet G, Savary S, Sarde CO, Mandel JL, Chi‐mini G (1996) A close relative of the adrenoleukodystrophy (ALD) gene codes for a peroxisomal protein with a specific expression pattern. Proc Natl Acad Sci USA 93: 1265–1269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Lu J‐F, Lawler AM, Watkins PA, Powers JM, Moser AB, Moser HW, Smith KD (1997) A mouse model for X‐linked adrenoleukodystrophy. Proc Natl Acad Sci USA 94: 9366–9371. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. MacDonald JT, Stauffer AE, Heitoff K (1984) Adrenoleukodystrophy: early frontal lobe involvement on computed tomography. J Comput Assist Tomogr 8: 128–130. [PubMed] [Google Scholar]
  • 59. Martinez M, Pineda M, Vidal R, Martin B (1993) Docosahexaenoic acid: A new therapeutic approach to peroxisomal patients. Experience with two cases. Neurology 43: 1389–1397. [DOI] [PubMed] [Google Scholar]
  • 60. Martinez M, Mougan I, Roig M, Ballabriga A (1994) Blood polyunsaturated fatty acids in patients with peroxisomal disorders. A multicenter study. Lipids 29: 273–280. [DOI] [PubMed] [Google Scholar]
  • 61. McGuinness MC, Griffin DE, Raymond GV, Washington CA, Moser HW, and Smith KD (1995) Tumor necrosis factor‐ and X‐linked adrenoleukodystrophy. J Neuroim-munol 61: 161–169. [DOI] [PubMed] [Google Scholar]
  • 62. McGuinness MC, Powers JM, Bias WB, Schmeckpepper BJ, Segal AH, Gowda VC, Wesselingh SL, Berger J, Griffin DE, Smith KD (1997) Human leukocyte antigens and cytokine expression in cerebral inflammatory demyelinative lesions of X‐linked adrenoleukodystrophy and multiple sclerosis. J Neuroimmunol 75: 174–182. [DOI] [PubMed] [Google Scholar]
  • 63. McGuire W, Hill AVS, Allsopp CEM, Greenwood BM, Kwiatkowski D (1994) Variation in the TNF‐alpha promotor region associated with susceptibility to cerebral malaria. Nature 371: 508–510. [DOI] [PubMed] [Google Scholar]
  • 64. Migeon BR, Moser HW, Moser AB, Axelman J, Sillence D, Norum RA (1981) Adrenoleukodystrophy: evidence for X‐linkage, inactivation, and selection favoring the mutant allele in heterozygous cells. Proc Natl Acad Sci USA 78: 5066–5070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Mihalik SJ, Morell SJ, Kim D, Watkins PA, Gould SJ (1997) Identification of PAHX, a Refsum disease gene. Nature Genet 17: 1–5. [DOI] [PubMed] [Google Scholar]
  • 66. Moser AB, Rasmussen M, Naidu S, Watkins PA, McGuinness M, Hajra AK, Chen G, Raymond G, Liu A, Gordon D, Garnaas K, Walton DS, Skjeldal OH, Guggenheim MA, Jackson LG, Elias ER, Moser HW (1995) Phenotype of patients with peroxisomal disorders subdivided into sixteen complementation groups. J Pediatr 127: 13–22. [DOI] [PubMed] [Google Scholar]
  • 67. Moser HW (1989) Peroxisomal diseases. In: Advances in Pediatrics, Barnes LAE (ed.), Volume 36, pp. 1–38, Year Book Medical Publishers: Chicago . [PubMed] [Google Scholar]
  • 68. Moser HW (1993) Peroxisomal diseases. In: Advances in Human Genetics, Harris H, Hirschhorn KE (eds.), Volume 21, pp. 1–106, Plenum Press: New York . [PubMed] [Google Scholar]
  • 69. Moser HW (1995) Komrower Lecture: Adrenoleukodystrophy: Natural history, treatment and outcome. J Inher Metab Dis 18: 435–447. [DOI] [PubMed] [Google Scholar]
  • 70. Moser HW (1997) Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 120: 1485–1508. [DOI] [PubMed] [Google Scholar]
  • 71. Moser HW, Smith KD, Moser AB (1995) X‐linked adrenoleukodystrophy. In: The Metabolic and Molecular Basis of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, Valle D (eds.), 7th Edition, Chapter 72, pp. 2325–2350, McGraw‐Hill: New York . [Google Scholar]
  • 72. Moser HW, Naidu S, Kumar AJ, Rosenbaum AE (1987) The Adrenoleukodystrophies. Crit Rev Neurobiol 3: 29–88. [PubMed] [Google Scholar]
  • 73. Moser HW, Moser AB, Naidu S, Bergin A (1991) Clinical aspects of adrenoleukodystrophy and adrenomyeloneu‐ropathy. Dev Neurosci 13: 254–261. [DOI] [PubMed] [Google Scholar]
  • 74. Moser HW, Aubourg P, Cornblath D, Borel J, Wu YW, Bergin A, Naidu S, Moser AB (1991) Therapy for X‐Linked adrenoleukodystrophy. In: Treatment of Genetic Diseases, Desnick RJ (ed.), pp. 111–129, Churchill Livingstone: New York . [Google Scholar]
  • 75. Moser HW, Moser AB, Smith KD, Bergin A, Borel J, Shankroff J, Stine OC, Merette C, Ott J, Krivit W, Shapiro E (1992) Adrenoleukodystrophy: phenotypic variability: Implications for therapy. J Inher Metab Dis 15: 645–664. [DOI] [PubMed] [Google Scholar]
  • 76. Moser HW, Powers JM, Smith KD (1995) Adrenoleukodystrophy: molecular genetics, pathology, and Lorenzo's oil. Brain Pathol 5: 259–266. [DOI] [PubMed] [Google Scholar]
  • 77. Mosser J, Douar AM, Sarde CO, Kioschis P, Feil R, Moser H, Poustka AM, Mandel JM, Aubourg P (1993) Putative X‐linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 361: 726–730. [DOI] [PubMed] [Google Scholar]
  • 78. Mosser J, Lutz Y, Stoeckel ME, Sarde CO, Kretz C, Douar AM, Lopez J, Aubourg P, Mandel JL (1994) The gene responsible for adrenoleukodystrophy encodes a peroxisomal membrane protein. Hum Mol Genet 3: 265–271. [DOI] [PubMed] [Google Scholar]
  • 79. Motley AM, Hettema EH, Hogenhout EH, Brites P, ten Asbroek A, Wijburg FA, Baas F, Heymans HSA, Tabak HF, Wanders RJA (1997) Rhizomelic chondrodysplasia punctata is a peroxisomal protein targeting disease caused by a non‐functional PTS2 receptor. Nature Genet 15: 377–380. [DOI] [PubMed] [Google Scholar]
  • 80. Murad S, Kishimoto Y (1978) Chain elongation of fatty acid in brain: a comparison of mitochondrial and microso‐mal enzyme activities. Arch Biochem Biophys 185: 300–306. [DOI] [PubMed] [Google Scholar]
  • 81. Odone A, Odone M (1989) Lorenzo's oil. A new treatment for adrenoleukodystrophy. J Pediatr Neurosci 5: 55–61. [Google Scholar]
  • 82. Poulos AS, Christodoulou J, Chow CW, Goldblatt J, Paton BC, Suzuki Y, Shimozawa N (1995) Peroxisomal assembly defects: Clinical, pathologic, and biochemical findings in two patients in a newly identified complementation group. J Pediatr 133: 1–3. [DOI] [PubMed] [Google Scholar]
  • 83. Powell H, Tindall R, Schultz P, Paa D, O'Brien J, Lampert P (1975) Adrenoleukodystrophy. Electron microscopic findings. Arch Neurol 32: 250–260. [DOI] [PubMed] [Google Scholar]
  • 84. Powers JM (1985) Adrenoleukodystrophy (adreno‐testiculo‐leuko‐myelo‐neuropathic‐complex). Clin Neuropathol 4: 181–199. [PubMed] [Google Scholar]
  • 85. Powers JM (1995) The pathology of peroxisomal disorders with pathogenetic considerations. J Neuropathol Exp Neurol 5: 710–719. [PubMed] [Google Scholar]
  • 86. Powers JM (1995) Peroxisomal diseases. In: Pediatric Neuropathology, Duckett S (ed.), Chapter 31, pp. 630–639, Williams & Wilkins: Baltimore . [Google Scholar]
  • 87. Powers JM (1996) A neuropathologic overview of the neurodystrophies and neurolipidoses. In: Handbook of Clinical Neurology, Vinken PJ, Bruyn GW (eds.), Neurodystrophies and Neurolipidoses, Moser HW (ed), Volume 66, Chapter 1, pp. 1–32, Elsevier: Amsterdam . [Google Scholar]
  • 88. Powers JM, Schaumburg HH (1974) Adreno‐leukodystrophy. Similar ultrastructural changes in adrenal cortical and Schwann cells. Arch Neurol 30: 406–408. [DOI] [PubMed] [Google Scholar]
  • 89. Powers JM, Schaumburg HH (1974) Adreno‐leukodystrophy (sex‐linked Schilder's disease). A pathogenetic hypothesis based on ultrastructural lesions in the adrenal cortex, peripheral nerve and testis. Am J Pathol 76: 481–492. [PMC free article] [PubMed] [Google Scholar]
  • 90. Powers JM, Schaumburg HH, Johnson AB, Raine CS (1980) A correlative study of the adrenal cortex in adrenoleukodystrophy ‐ evidence for a fatal intoxication with very long chain fatty acids. Invest Cell Pathol 3: 353–376. [PubMed] [Google Scholar]
  • 91. Powers JM, Schaumburg HH (1981) The testis in adrenoleukodystrophy. Am J Pathol 102: 90–98. [PMC free article] [PubMed] [Google Scholar]
  • 92. Powers JM, Moser HW, Moser AB, Schaumburg HH (1982) Fetal adrenoleukodystrophy. The significance of pathologic lesions in adrenal gland and testis. Hum Pathol 13: 1013–1019. [DOI] [PubMed] [Google Scholar]
  • 93. Powers JM, Tummons RC, Moser AB, Moser HW, Hoft DS, Kelley Rl (1987) Neuronal lipidosis and neuroaxonal dystrophy in cerebro‐hepato‐renal (Zellweger) syndrome. Acta Neuropathol (Berl) 73: 333–343. [DOI] [PubMed] [Google Scholar]
  • 94. Powers JM, Tummons RC, Caviness VS, Moser AB, Moser HW (1989) Structural and chemical alterations in the cerebral maldevelopment of fetal cerebro‐hepato‐renal (Zellweger) syndrome. J Neuropathol Exp Neurol 48: 270–289. [DOI] [PubMed] [Google Scholar]
  • 95. Powers JM, Liu Y, Moser AB, Moser HW (1992) The inflammatory myelinopathy of adreno‐leukodystrophy: Cells, effector molecules and pathogenetic implications. J Neuropathol Exp Neurol 51: 630–643. [DOI] [PubMed] [Google Scholar]
  • 96. Powers JM, Moser AB, Moser HW (1993) The myelopathy of adrenomyeloneuropathy. (abstract). J Neuropathol Exp Neurol 52:332. [DOI] [PubMed] [Google Scholar]
  • 97. Powers JM, Moser AB, Moser HW (1997) Cerebellar degeneration in rhizomelic chondrodysplasia punctata. (abstract). J Neuropathol Exp Neurol 56:590. [Google Scholar]
  • 98. Powers JM, Moser AB, Moser HW (1997) Neuronal degenerations in peroxisomal disorders. Brain Pathol 7: 1315–1316. [Google Scholar]
  • 99. Probst A, Ulrich J, Heitz PU, Herschkowitz N (1977) Adrenomyeloneuropathy. Acta Neuropathol (Berl) 49: 105–115. [DOI] [PubMed] [Google Scholar]
  • 100. Purdue PE, Takada T, Danpure CJ (1990) Identification of mutations associated with peroxisome‐to‐mitochondrion mistargeting of alanine/glyoxylate aminotransferase in primary hyperoxaluria type I. J Cell Biol 111: 2341–2351. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 101. Purdue PE, Zhang JW, Skoneczny M, Lazarow PB (1997) Rhizomelic chondrodysplasia punctata is caused by deficiency by human PEX 7, a homologue of the yeast PTS2 receptor. Nature Genet 15: 381–384. [DOI] [PubMed] [Google Scholar]
  • 102. Refsum S (1946) Heredopathia atactica polyneuritiformis. A familial syndrome not hitherto described. Acta Psychatr Scand Suppl 38: 1–303. [Google Scholar]
  • 103. Rizzo WB, Watkins PA, Phillips MW, Cranin D, Campbell B, Avigan J (1986) Adrenoleukodystrophy: oleic acid lowers fibroblast saturated C22–26 fatty acids. Neurology 36: 357–361. [DOI] [PubMed] [Google Scholar]
  • 104. Rodriguez, Gordon WC, Peyman GA, Bazan NG (1990) Preferential uptake and metabolism of docosahexaenoic acid in membrane phospholipids from rod and cone photoreceptor cells of human and monkey retinas. J Neurosci Res 27: 522–532. [DOI] [PubMed] [Google Scholar]
  • 105. Satoh S, Monma N, Satoh T, Satodate R, Saiki K (1986) Adrenoleukodystrophy. Report of an autopsy case with adrenomyeloneuropathy. Acta Pathol Jpn 36: 1055–1066. [PubMed] [Google Scholar]
  • 106. Schram AW, Goldfischer S, Van Roermund CWT, Brouwer‐Kelder EM, Collins J, Hashimoto T, Heymans HSA, van Den Bosch H, Schutgens RBH, Tager JM, Wanders RJA (1987) Human peroxisomal 3‐oxoacyl‐coenzyme A thiolase deficiency. Proc Natl Acad Sci USA 84: 2494–2496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 107. Schaumburg HH, Powers JM, Suzuki K, Raine CS (1974) Adreno‐leukodystrophy (sex‐linked Schilder disease). Ultrastructural demonstration of specific cytoplasmic inclusions in the central nervous system. Arch Neurol 31: 210–213. [DOI] [PubMed] [Google Scholar]
  • 108. Schaumburg HH, Powers JM, Raine CS, Suzuki K (1975) Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Arch Neurol 33: 577–591. [DOI] [PubMed] [Google Scholar]
  • 109. Schaumburg HH, Powers JM, Raine CS, Spencer PS, Griffin JW, Prineas JW, Boehme DM (1977) Adrenomyeloneuropathy: A probable variant of adrenoleukodystrophy. II. General pathologic, neuropathologic and biochemical aspects. Neurology 27: 1114–1119. [DOI] [PubMed] [Google Scholar]
  • 110. Shani N, Steel G, Dean M, Valle D (1996) Four half ABC transporters may heterodimerize in the peroxisomal membrane. Am J Hum Genet 59: A42. [DOI] [PubMed] [Google Scholar]
  • 111. Shimozawa N, Tsukamoto T, Suzuki Y, Orii T, Shirayoshi Y, Mori T, Fujiki Y (1992) A human gene responsible for Zell‐weger syndrome that affects peroxisome assembly. Science 255: 1132–1134. [DOI] [PubMed] [Google Scholar]
  • 112. Sobue G, Ueno‐Natsukari I, Okamoto H, Connell TA, Aizawa I, Mizoguchi K (1994) Phenotypic heterogeneity of an adult‐form of adrenoleukodystrophy in monozygotic twins. Ann Neurol 36: 912–915. [DOI] [PubMed] [Google Scholar]
  • 113. Spector AA (1975) Fatty acid binding to plasma albumin. (Review). J Lipid Res 16: 165–179. [PubMed] [Google Scholar]
  • 114. Steinberg D (1995) Refsum disease. In: The Metabolic and Molecular Basis of Inherited Disease, Scriver CR, Beaudet AL, Sly WS, Valle D (eds.), 7th Edition, Chapter 73, pp. 2351–2369, McGraw‐Hill: New York . [Google Scholar]
  • 115. Steinberg D, Vroom FQ, Engel WK, Cammermeyer J, Mize CE, Avigan J (1967) Refsum's disease ‐ a recently characterized lipidosis involving the nervous system. Ann Intern Med 66: 365–395. [DOI] [PubMed] [Google Scholar]
  • 116. Theda C, Moser AB, Powers JM, Moser HW (1992) Phospholipids in X‐linked adrenoleukodystrophy white matter. Fatty acid abnormalities before the onset of demyelination. J Neurol Sci 110: 195–204. [DOI] [PubMed] [Google Scholar]
  • 117. Torvik A, Torp S, Kase BF, Ek J, Skjeldal O, Stokke O (1988) Infantile Refsum's disease: A generalized peroxisomal disorder. Case report with postmortem examination. J Neurol Sci 85: 39–53. [DOI] [PubMed] [Google Scholar]
  • 118. Tsuji S, Sano‐Kawamura T, Ariga T, Miyatake T (1985) Metabolism of (17, 18–3H2) hexacosanoic acid and (15,16‐3H2) lignoceric acid in cultured skin fibroblasts from patients with adrenoleukodystrophy (ALD) and adrenomyeloneuropathy (AMN). J Neurol Sci 71: 359–367. [DOI] [PubMed] [Google Scholar]
  • 119. Van Geel BM, Koelman JH, Barth PG, Ongerboer de Visser BW (1996) Peripheral nerve abnormalities in adrenomyeloneuropathy: a clinical and electrodiagnostic study. Neurology 46: 112–118. [DOI] [PubMed] [Google Scholar]
  • 120. Volpe JJ, Adams RD (1972) Cerebro‐hepato‐renal syndrome of Zellweger. An inherited disorder of neuronal migration. Acta Neuropathol (Berl) 20: 175–198. [DOI] [PubMed] [Google Scholar]
  • 121. Wanders RJA, Heymans HSA, Schutgens RBH, Barth PG, van den Bosch H, Tager JM (1988) Peroxisomal disorders in neurology. J Neurol Sci 88: 1–39. [DOI] [PubMed] [Google Scholar]
  • 122. Wanders RJA, Schumacher H, Heikoop J, Schutgens RBH, Tager JM (1992) Human dihydroxyacetone phosphate acyltransferase deficiency: A new peroxisomal disorder. J Inher Metab Dis 15: 389–391. [DOI] [PubMed] [Google Scholar]
  • 123. Wanders RJA, Decker C, Horvath VAP, Schutgens RBH, Tager JM, Van Laer P, Lecoutere D (1994) Human alkyldihydroxyacetone phosphate synthase deficiency: A new peroxisomal disorder. J Inher Metab Dis 17: 315–318. [DOI] [PubMed] [Google Scholar]
  • 124. Wanders RJA, Schutgens RBH, Barth PG (1995) Peroxisomal disorders. J Neuropathol Exp Neurol 54: 726–739. [DOI] [PubMed] [Google Scholar]
  • 125. Wanders RJA, Barth PG, Schutgens RBH, Heymans HSA (1996) Peroxisomal disorders: Post‐ and prenatal diagnosis based on a new classification with flow charts. Int Pediatr 11: 203–214. [Google Scholar]
  • 126. Wanders RJA, Heymans HSA, Schutgens RBH, Barth PG (1996) Generalized peroxisomal disorders and disorders of peroxisomal fatty acid oxidation. In: Handbook of Clinical Neurology, Vinken PJ, Bruyn GW (eds.), Neurodystrophies and Neurolipidoses, Moser HW (ed), Volume 66, Chapter 23, pp. 505–524, Elsevier Science Publishers: Amsterdam . [Google Scholar]
  • 127. Wanders RJA, Denis S, Wouters F, Wirtz KWA, Seedor U (1997) Sterol carrier protein X (SCPx) is a peroxisomal branched‐chain beta‐ketothiolase specifically reacting with 3‐oxo‐pristanoyl‐CoA: A new, unique role for SCPx in branched‐chain fatty acid metabolism in peroxisomes. Biochem Biophys Res Commun 236: 565–569. [DOI] [PubMed] [Google Scholar]
  • 128. Watkins PA, Chen WW, Harris CJ, Hoefler G, Hoefler S, Blake DC, Balfe A, Kelley RI, Moser AB, Beard ME, Moser HW (1989) Peroxisomal bifunctional enzyme deficiency. J Clin Invest 83: 771–777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 129. Watkins PA, Gould SJ, Smith MA, Braiterman LT, Wei HM, Kok F, Moser AB, Moser HW, Smith KD (1995) Altered expression of ALDP in X‐linked adrenoleukodystrophy. Am J Hum Genet 57: 292–301. [PMC free article] [PubMed] [Google Scholar]
  • 130. Watkins PA, McGuinness MC, Raymond GV, Hicks BA, Sisk JM, Moser AB, Moser HW (1995) Distinction between peroxisomal bifunctional enzyme and acyl‐CoA oxidase deficiencies. Ann Neurol 38: 472–477. [DOI] [PubMed] [Google Scholar]
  • 131. Whitcomb RW, Linehan WM, Knazek RA (1988) Effects of long‐chain saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro. J Clin Invest 81: 185–188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132. Wilson R, Tocher DR, Sargent JR (1992) Effects of exogenous monounsaturated fatty acids or fatty acid metabolism in cultured skin fibroblasts from adrenoleukodystrophy patients. J Neurol Sci 109: 207–214. [DOI] [PubMed] [Google Scholar]
  • 133. Yahraus T, Braverman N, Dodt G, Kalish JE, Morrell JC, Moser HW, Valle D, Gould SJ (1996) The peroxisome biogenesis disorder group 4 gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the PTS1 receptor. EMBO J 15: 2914–2923. [PMC free article] [PubMed] [Google Scholar]
  • 134. Yakovac WC (1954) Calcareous chondropathies in the newborn infant. Arch Pathol 57: 62–77. [PubMed] [Google Scholar]
  • 135. Young RSK, Ramen JC, Towfighi J, Weidner W, Lehman R, Moser HW (1982) Adrenoleukodystrophy: unusual computed tomographic appearance. Arch Neurol 39: 782–783. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES